🔗 Visit the ClinicalTrials.gov page for NCT02141542
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. | Eur J Cancer | 2015 | 1.53 |
| 2 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. | Oncoimmunology | 2015 | 1.06 |
| 3 | Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. | J Clin Invest | 2015 | 0.98 |
| 4 | Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. | Front Oncol | 2015 | 0.92 |
| 5 | Challenges and future perspectives of T cell immunotherapy in cancer. | Immunol Lett | 2015 | 0.78 |
| 6 | Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. | J Immunother Cancer | 2016 | 0.75 |
| 7 | The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. | Oncoimmunology | 2016 | 0.75 |